A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Fragment-based screening with natural products for novel anti-parasitic disease drug discovery
2019
Expert Opinion on Drug Discovery
Fragment-based drug discovery can identify relatively simple compounds with low binding affinity due to fewer binding interactions with protein targets. FBDD reduces the library size and provides simpler starting points for subsequent chemical optimization of initial hits. A much greater proportion of chemical space can be sampled in fragment-based screening compared to larger molecules with typical molecular weights (MWs) of 250-500 g mol-1 used in high-throughput screening (HTS) libraries.
doi:10.1080/17460441.2019.1653849
pmid:31512943
pmcid:PMC6816479
fatcat:6w5f3awxqrbphoanmaoyqo3ewa